FMP
Millendo Therapeutics, Inc.
MLND
NASDAQ
Inactive Equity
Millendo Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing novel treatments for orphan endocrine diseases in the United States. Its lead product candidates include livoletide, a potential treatment for Prader-Willi syndrome; nevanimibe, a potential treatment for patients with classic congenital adrenal hyperplasia; and MLE-301, a neurokinin 3-receptor antagonist for the treatment of vasomotor symptoms in menopausal women. The company is headquartered in Ann Arbor, Michigan.
1.06 USD
-0.06000006 (-5.66%)
MLND Financial Statements
Year
2020
2019
2018
2017
Total Revenue
0
0
0
295k
Cost of Revenue
0
0
0
790k
Gross Profit
0
0
0
-495k
Operating Expenses
35.97M
45.4M
26.87M
46.08M
Research and Development
20.37M
27.84M
14.43M
18.34M
Selling, General & Administrative Expenses
15.6M
17.56M
12.45M
0
Selling & Marketing Expenses
0
0
0
0
General & Administrative Expenses
15.6M
17.56M
12.45M
0
Other Expenses
0
0
0
27.74M
Operating Income
-35.97M
-45.4M
-26.87M
-46.58M
Total Other Income/Expenses Net
-434k
831k
-303k
-4.33M
Income Before Tax
-36.41M
-44.57M
-27.18M
-50.91M
Income Tax
-434k
-207k
-169k
67k
Net Income
-36.41M
-44.57M
-27.19M
-50.98M
Basic EPS
-28.95
-48.77
-263.65
-321.49
EPS Diluted
-28.95
-48.77
-263.65
-321.49
Basic Average Shares
1.26M
913.79k
103.14k
158.56k
Diluted Average Shares
1.26M
913.79k
103.14k
158.56k
EBITDA
-35.3M
-44.55M
-27.03M
-49.26M
Retained Earning Schedule
Year
2020
2019
2018
2017
Retained Earnings (Previous Year)
-208.65M
-164.09M
-301.48M
-250.18M
Net Income
-36.41M
-44.57M
-27.19M
-50.98M
Stock Repurchases
0
0
0
0
Dividend Paid
0
0
0
0
Retained Earnings
-245.06M
-208.65M
-164.09M
-301.48M
Other Distributions
-36.41M
-44.57M
137.39M
-51.3M
PPE Schedule
Year
2020
2019
2018
2017
Gross PPE
2.16M
3.33M
0
3.11M
Annual Depreciation
1.1M
1.05M
32k
1.65M
Capital Expenditure
-26k
-397k
-36k
-158k
Net PPE
1.08M
2.68M
4k
1.62M
Intangible and Goodwill Schedule
Year
2020
2019
2018
2017
Acquisitions and Adjustments
0
0
0
0
Goodwill (Previous Year)
0
0
0
0
Goodwill
0
0
0
0
All figures are in USD.
